Discovery and development of GG745, a potent inhibitor of both isozymes of 5 alpha-reductase
Frye, S.V.; Bramson, H.N.; Hermann, D.J.; Lee, F.W.; Sinhababu, A.K.; Tian, G.
Pharmaceutical Biotechnology 11: 393-422
1998
ISSN/ISBN: 1078-0467 PMID: 9760689 Document Number: 493533
Document emailed within 1 workday
Related Documents
Van Heek, M.; France, C.F.; Compton, D.S.; McLeod, R.L.; Yumibe, N.P.; Alton, K.B.; Sybertz, E.J.; Davis, H.R. 1997: In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461 Journal of Pharmacology and Experimental Therapeutics 283(1): 157-163Adkison, K.K.; Halm, K.A.; Shaffer, J.E.; Drewry, D.; Sinhababu, A.K.; Berman, J. 1998: Discovery of a potent and selective alpha 1A antagonist. Utilization of a rapid screening method to obtain pharmacokinetic parameters Pharmaceutical Biotechnology 11: 423-443
Cabeza, M.; Bratoeff, E.; Heuze, I.; Ramírez, E.; Sánchez, M.; Flores, E. 2003: Effect of beta-sitosterol as inhibitor of 5 alpha-reductase in hamster prostate Proceedings of the Western Pharmacology Society 46: 153-155
Matzkin, H.; Chayen, R.; Goldfarb, H.; Gilad, S.; Braf, Z. 1992: Laboratory monitoring of androgenic activity in benign prostate hypertrophy treated with a 5 alpha-reductase inhibitor Clinical Chemistry 38(7): 1304-1306
Hansen, B.J.; Hvidt, V. 1993: Finasteride. a new 5 alpha reductase inhibitor registered for treatment of benign prostatic hypertrophy with the purpose of avoiding or postponing surgery Ugeskrift for Laeger 155(50): 4110-4112
Kotyla, P.J.; Sliwinska-Kotyla, B.; Kucharz, E.J. 2006: Tumor necrosis factor-alpha as a potential target in the treatment of systemic lupus erythematosus: a role for the HMG-CoA reductase inhibitor simvastatin Journal of rheumatology 33(11): 2361-3; author reply 2363
Brown, A.G. 1986: Clavulanic acid, a novel beta-lactamase inhibitor--a case study in drug discovery and development Drug Design and Delivery 1(1): 1-21
Gaillard, M.C.; Reichberg, S.B.; Nogueira, C.M.; Kilroe-Smith, T.A. 1993: Differences in elastase-binding activity of alpha 1-protease inhibitor and alpha 2-macroglobulin for asthma patients and control subjects with various alpha 1-protease inhibitor phenotypes Clinical Chemistry 39(4): 675-679
Reyes, E.F.; Virgo, B.B. 1988: Neonatal programming of ethylmorphine demethylase and corticosteroid 5 alpha-reductase by testosterone, dihydrotestosterone, and estradiol. Effects of an anti-estrogen, an anti-androgen, and an inhibitor of estrogen synthetase Drug Metabolism and Disposition: the Biological Fate of Chemicals 16(1): 93-97
Fukuda, C.; Iijima, K.; Inoue, N.; Takashima, Y.; Urabe, C.; Nakamura, K. 1988: Clinical evaluation of alpha 2 plasmin inhibitor and alpha 2 plasmin inhibitor-plasmin complex by enzyme immunoassay method--with special reference to accident surgery Rinsho Byori. Japanese Journal of Clinical Pathology 36(3): 346-350
Ajanki, T.; Laborit, H. 2005: "A drug potent enough to cause artificial hibernation". Discovery of chlorpromazine changed psychiatry Lakartidningen 102(3): 144-145
Travis, J.; Beatty, K.; Wong, P.S.; Matheson, N.R. 1980: Oxidation of alpha 1-proteinase inhibitor as a major, contributing factor in the development of pulmonary emphysema Bulletin Europeen de Physiopathologie Respiratoire 16(Suppl): 341-352
Aarthy, M.; Singh, S.Kumar. 2018: Discovery of Potent Inhibitors for the Inhibition of Dengue Envelope Protein: An In Silico Approach Current Topics in Medicinal Chemistry 18(18): 1585-1602
2003: 5-alpha reductase inhibitors plus alpha blockers. A combination therapy keeps a common disease checked MMW Fortschritte der Medizin 145(27-28): 58-59
Kamiya, T.; Takamatsu, J.; Koie, K.; Kohakura, M. 1981: Metabolism of alpha 2-plasmin inhibitor ( alpha 2-PI) in a patient with congenital alpha 2-Pi deficiency Nihon Ketsueki Gakkai Zasshi: Journal of Japan Haematological Society 44(7): 1513-1519
Mollison, K.W.; Fey, T.A.; Gauvin, D.M.; Sheets, M.P.; Smith, M.L.; Pong, M.; Krause, R.; Miller, L.; Or, Y.S.; Kawai, M.; Wagner, R.; Wiedeman, P.E.; Clark, R.F.; Gunawardana, I.W.; Rhoades, T.A.; Henry, C.L.; Tu, N.P.; BaMaung, N.Y.; Kopecka, H.; Liu, L.; Xie, Q.; Lane, B.C.; Trevillyan, J.M.; Marsh, K.; Luly, J.R. 1998: Discovery of ascomycin analogs with potent topical but weak systemic activity for treatment of inflammatory skin diseases Current Pharmaceutical Design 4(5): 367-379
Isley, W.L.. 2001: Pitavastatin (NK-104), a new HMG-CoA reductase inhibitor Drugs of Today 37(9): 587-594
Murphy, N.R.; Leinbach, S.S.; Hellwig, R.J. 1995: A potent, cost-effective RNase inhibitor Biotechniques 18(6): 1068-1073
Rémy, A.; Avouac, J.; Gossec, L.; Combe, B. 2011: Clinical relevance of switching to a second tumour necrosis factor-alpha inhibitor after discontinuation of a first tumour necrosis factor-alpha inhibitor in rheumatoid arthritis: a systematic literature review and meta-analysis Clinical and Experimental Rheumatology 29(1): 96-103
Wen, X.; Wang, J.S.; Backman, J.T.; Kivistö, K.T.; Neuvonen, P.J. 2001: Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9 Drug Metabolism and Disposition: the Biological Fate of Chemicals 29(11): 1359-1361